sar425899 glp-1 glucagon dual agonist sanofi Transforming obesity: The advancement of multi-receptor drugs: Cell First clinical PET study measuring

By 2030, the global prevalence of obesity is expected to reach one billion

Explore the science behind patches vs oral options and uncover which alternatives have the strongest evidence.

Compounded GLP-1 drugs are going away Suggested Caption: The shortage of name-brand GLP-1 drugs has ended, and less expensive compounded GLP-1 drugs will no longer be available

The clinical data is real

Official supply shortages persisted for most of 2024, as surging demand for AOMs continued to outstrip product supply, despite limited reimbursement, which presented an opportunity quickly seized upon by U.S

However, most (59%) of same those employers say their cost for the drugs has exceeded expectations